AFT Pharmaceuticals Ltd (ASX: AFP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AFT Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $439.65 million
P/E Ratio 59.17
Dividend Yield N/A
Shares Outstanding 104.65 million
Earnings per share 0.075
Dividend per share N/A
Year To Date Return -17.49%
Earnings Yield 1.69%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

AFT Pharmaceuticals Ltd (ASX: AFP)
Latest News

AFP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AFT Pharmaceuticals Ltd

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Coco-scalp, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Southeast Asia and the Rest of the world. It generates the majority of the revenue from Australia whichincludes the sales and distribution activity relating to the Australian market.

AFP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
28 Jul 2021 $4.20 $-0.13 -3.00% 1,652 $4.20 $4.33 $4.20
27 Jul 2021 $4.33 $-0.02 -0.46% 5,490 $4.33 $4.33 $4.20
23 Jul 2021 $4.35 $0.00 0.00% 116 $4.35 $4.35 $4.35
22 Jul 2021 $4.35 $0.00 0.00% 204 $4.35 $4.35 $4.35
20 Jul 2021 $4.35 $0.00 0.00% 450 $4.35 $4.35 $4.35
14 Jul 2021 $4.35 $0.08 1.87% 1,223 $4.27 $4.35 $4.27
12 Jul 2021 $4.27 $-0.10 -2.29% 593 $4.34 $4.34 $4.27
09 Jul 2021 $4.37 $0.12 2.82% 3,600 $4.36 $4.37 $4.36
07 Jul 2021 $4.25 $-0.14 -3.19% 121,284 $4.25 $4.25 $4.25
06 Jul 2021 $4.39 $0.19 4.52% 12,325 $4.16 $4.39 $4.10
05 Jul 2021 $4.20 $0.00 0.00% 13,950 $4.21 $4.21 $4.20
02 Jul 2021 $4.20 $0.00 0.00% 11,301 $4.17 $4.20 $4.16

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 Aug 2020 Hartley Atkinson Issued 730 $3,029,500
Conversion of securities. Trading in $NZD.
As per announcement on 10/08/2020.
07 Aug 2020 Hartley Atkinson Issued 137 $377,643
Issue of securities. Trading in $NZD.
07 Aug 2020 Hartley Atkinson Exercise 730 $3,029,500
Conversion of securities. Trading in $NZD.
As per announcement on 10/08/2020.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Jon Lamb Non-Executive Director Sep 2012
Mr Lamb has led the planning, marketing and restructuring of companies throughout his career. He has held roles at Beecham including CEO in New Zealand and Marketing Manager in both Australia and South Africa. He has also held roles as CEO of Nylex in New Zealand, Managing Director within the Rural Division of Fletcher Challenge, Director of Southland Frozen Meats and Marketing Director of the New Zealand Kiwifruit Marketing Board. He was a Director of Virionyx, a New Zealand company that developed an antiviral drug designed to combat AIDS. He was Deputy Chair of Australian diagnostic company ATF Group that developed a real time tool for measuring the Hepatitis B virus in individual patients. He serves as a director of Coronation Equities Limited, Culture Check Limited, Project X Trustee Limited, Three Dots Limited, Redvers Limited, Indica Industries NZ Limited, Medreleaf NZ Limited and was a director of Zoono Limited. He is also a trustee of Rivers One Limited. He serves as a chair of the Risk Committee.
Mr David Mark Flacks Non-Executive ChairmanNon-Executive Director Jun 2015
Mr Flacks is a director of a environmentally pro bono organisations. He is a former chair of the NZX Markets Disciplinary Tribunal and a former member of the Takeovers Panel. He is also a director of boutique corporate law firm Flacks & Wong. He was a senior corporate partner at Bell Gully and was general counsel and company secretary of Carter Holt Harvey during the 1990's. He is also chair of the Regulatory Governance Committee of the NZX, chair of the Suncorp NZ group of companies, Harmoney Corp Limited, Upside Biotechnologies Limited. He is a director of Vero Insurance New Zealand Limited, Vero Liability Insurance New Zealand Limited Asteron Life Limited. He was a director of NZ Venture Investment Fund. He is a member of the Risk Committee.
Dr John Douglas Wilson Non-Executive Director Sep 2012
Dr Wilson was an Associate Professor at the Auckland Medical School before taking a role as Senior Vice President and Head of Medicine and Regulatory Affairs in the US for German drug company Boehringer Ingelheim Pharmaceuticals. He then carried these same responsibilities to Boehringer's worldwide medical research group in Germany, overseeing all research and drug development programmes. He supervised sixteen drugs to the US market through FDA and others into global markets. He has been a consultant to pharmaceutical and biotech companies in New Zealand, Australia, Italy, the UK, Ireland and New York. He was a consultant of Ferghana Partners Inc. He has been a director of Neuren Pharmaceuticals, of a drug discovery company Phylogica in Perth Australia, and of Adherium - a medical device company. He is currently a consultant to the Ryman Healthcare clinical governance committee. He is a director of Mainz Consulting Limited. He is also a member of Commercial Committee at Malaghan Institute. He is a chairman of Regulatory and Product Development Oversight Committee.
Ms Marree Atkinson Chief of StaffManaging Director Sep 2012
Ms Atkinson has held roles in sales, regulatory affairs, customer services and logistics. She is a registered nurse previously practising at Waikato Hospital.
Mr Hartley Atkinson FounderChief Executive OfficerExecutive Director Sep 1997
Mr Atkinson worked at Swiss multinational pharmaceutical company, Roche, for eight years where he held positions as Sales & Marketing Director, Medical Director, Product Manager and Medical Manager. Prior to his work at Roche, he was a Drug Information Pharmacist and Researcher at the Department of Clinical Pharmacology, Christchurch Hospital. He is the author of a of scientific publications. His work has been published in the - The New England Journal of Medicine.
Mr James (Jim) Burns Non-Executive Director Sep 2015
Mr Burns has executive experience in pharmaceuticals, biotechnology, medical devices, and diagnostics. He has served in leadership roles at multinational corporations, early-stage companies, venture capital funds and private equity. From 2009-2016, he served as Chairman of the Board, Executive Chairman and Chief Executive Officer of Assurex Health, a precision medicine company focused on neuropsychiatric and pain disorders. Previous roles include President & CEO of cancer drug development company CASI Pharmaceuticals; President of MedPointe Pharmaceuticals, a specialty pharmaceutical company; President & CEO of biotechnology company Osiris Therapeutics; General Partner of Healthcare Ventures; Group President of Becton Dickinson, a global medical device company; and Partner at Booz & Company, an international consulting firm. He is a director of Director of Vermillion, Inc., Precera Bioscience Inc., and VisionGate Inc. He is also a director and executive chairman of Phenomics Health Inc. He is a member of the Risk Committee.
Ms Anita Baldauf Non-Executive Director Nov 2020
Ms Baldauf has experience in international business development, finance, compliance, personnel development and governance through her 22-year career with Nestle. More recently she has been advising New Zealand start-ups and new ventures as they navigate through the challenges of growth and changing market environments. Ms Baldauf, who is also a fellow of the Edmund Hillary Fellowship.
Dr Ted Witek Non-Executive Director Jan 2021
Dr Witek has more than three decades of international clinical development and leadership experience. Between 2014 and 2018 Dr Witek served as Senior Vice President, Corporate Partnerships, and Chief Scientific Officer at Innoviva in San Francisco. Prior to that he spent more than two decades, mainly in the US, with Boehringer Ingelheim where he rose to the role of President and CEO of the multi-national's Canadian and Portuguese operations. He has served on the boards of numerous professional societies including the Board of Directors of Canada's Research-Based Pharmaceutical Companies (Rx&D) and the Drug/Device Discovery and Development Committee of the American Thoracic Society. He has also served on the boards of numerous advisory organisations and companies including the Government of Ontario Health Innovation Council, Columbia University Health and Innovation Technology Lab, Lumira Ventures and Trudell Medical International. He has also authored more than 100 scientific publications in the fields of respiratory health, public health, airway disease, and drug development and is a reviewer for numerous scientific journals.
Mr Malcolm Tubby Chief Financial OfficerCompany Secretary
-
Malcolm Tubby Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hartley Atkinson & Colin Mckay 72,899,435 69.66%
Accident Compensation Corporation Nzcsd 4,379,184 4.18%
MMC Limited 2,838,384 2.71%
FNZ Custodians Limited 2,599,493 2.48%
Forsyth Barr Custodians Limited 2,125,725 2.03%
BNP Paribas Nominees (Nz) Limited - Nzscd 1,930,087 1.84%
Citicorp Nominees Pty Limited 1,094,231 1.05%
HSBC Nominees (New Zealand) - Nzcsd 932,220 0.89%
HSBC Nominees A/C Nz Superannuation Fund Nominees Limited Nzcsd 854,404 0.82%
Tea Custodians Limited Client Property Trust Account Nzcsd 763,023 0.73%
New Zealand Depository Nominee Limited 692,299 0.66%
BNP Paribas Nominees (Nz) Limited Nzscd I 651,770 0.62%
Jp Morgan Nominees Australia Limited 529,815 0.51%
FNZ Custodians Limited I 502,990 0.48%
Cs Third Nominees Pty Limited 344,761 0.33%
Custodial Services Limited 297,000 0.28%
Rivers One Limited 221,305 0.21%
Hamish Stewart Atkinson & Karen Winifred Atkinson & Andrew John Marriott 203,333 0.19%
FNZ Custodians Limited II 203,253 0.19%
BNP Paribas Nominees (Nz) Limited Nzscd 199,283 0.19%

Profile

since

Note